Current Report Filing (8-k)
October 11 2022 - 8:01AM
Edgar (US Regulatory)
0001444307
false
0001444307
2022-10-07
2022-10-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 7, 2022
ONCOSEC
MEDICAL INCORPORATED
(Exact
Name of Registrant as Specified in Charter)
Nevada |
|
000-54318 |
|
98-0573252 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
24
North Main Street, Pennington, NJ |
|
08534-2218 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (855) 662-6732
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
symbol |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.0001 per share |
|
ONCS |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
Effective
October 7, 2022, the Board of Directors (the “Board”) of OncoSec Medical Incorporated (the “Company”) elected
Stephany Foster as an independent director of the Board and also appointed Ms. Foster as Chair of the Audit Committee of the Board and
member of the Compensation Committee of the Board.
Ms.
Foster has over 20 years of experience in the fields of accounting and human resource management. Since October 2019, Ms. Foster has
served as Chief Human Resources Officer, Senior Vice President, Head of Global Human Resources, and a member of the Executive Committee
of QIAGEN N.V., a global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples
containing the building blocks of life. Prior to this position, Ms. Foster served as Vice President, Head of Compensation and Benefits,
at QIAGEN from January 2019, and earlier as Vice President, Head of Internal Audit, at QIAGEN from January 2005 to December 2018. Ms.
Foster holds both a Bachelor’s and Master’s degree in Accounting from the University of Notre Dame.
Ms.
Foster will be compensated for her service on the Board in accordance with the Company’s compensatory and other arrangements for
non-employee independent directors, which are described in the Company’s definitive proxy statement filed with the Securities and
Exchange Commission on May 31, 2022. Ms. Foster was awarded 50,000 stock option awards upon joining the Board, which stock options will
vest quarterly, commencing on the first completed calendar quarter after the date of grant, subject to Ms. Foster’s continuous
service on the Board through each such vesting date.
There
are no transactions between Ms. Foster and the Company that would require disclosure under Item 404(a) of Regulation S-K.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
October 11, 2022 |
OncoSec
Medical Incorporated |
|
|
|
|
By:
|
/s/
Robert H. Arch |
|
Name: |
Robert
H. Arch |
|
Title: |
President
and Chief Executive Officer |
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024